This looked at patients with transplant-eligible newly diagnosed multiple myeloma, and randomly assigned the patients ... I ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

With a median follow-up duration of 55 months, the tandem ASCT group had a median PFS of 42 months compared with 62 months in the single ASCT group. In a real-world study involving patients with ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

The Northern BC Myeloma Support Group has been recognized by its parent national organization for going the extra mile in its ...